[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 16 of about 16
1. Sperotto A, Silvestri F, Fanin R, Damiani D, Geromin A, Cerno M, Stocchi R, Patriarca F, Baccarani M: Feasibility of autologous stem cell transplantation in chronic carriers of hepatitis B and hepatitis C virus. Leuk Lymphoma; 2000 Jan;36(3-4):323-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of autologous stem cell transplantation in chronic carriers of hepatitis B and hepatitis C virus.
  • There are several reports describing acute liver decompensation in chronic carriers of HBsAg after withdrawal of chemotherapy or immunosuppressive therapy; recently the same was also reported for chronic HCV-RNA carriers.
  • We retrospectively evaluated hepatic toxicity in eleven patients (6 carriers of HCV-RNA and 5 of HBsAg) autotransplanted at our Institution between March '92 and June '98.
  • Nine patients (4 HBsAg) were affected by non-Hodgkin's lymphoma, 1 (HCV-RNA) by chronic myelogenous leukaemia and 1 (HBsAg) by breast cancer.
  • In the immediate post-transplant period in only 1 patient (HBsAg carrier and affected by breast cancer) was hepatitis documented (at about 1 month from transplant) with an elevation of transaminase levels (x20-40 n.v.).
  • All patients are alive at 56 months (20-122) from diagnosis.
  • Currently 10/11 patients are in complete remission, while 1 patient, affected by follicular centre lymphoma, is alive with disease 52 months from autologous stem cell transplantation.
  • Our study shows that both conventional therapy and high-dose chemotherapy can be performed safely in chronic hepatitis B and C virus carriers.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hepatitis B, Chronic / complications. Hepatitis C, Chronic / complications. Lymphoma / complications. Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Busulfan / therapeutic use. Carrier State. Feasibility Studies. Female. Follow-Up Studies. Humans. Liver / drug effects. Liver / metabolism. Male. Melphalan / therapeutic use. Middle Aged. Transplantation Conditioning. Transplantation, Autologous

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10674904.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; G1LN9045DK / Busulfan; Q41OR9510P / Melphalan
  •  go-up   go-down


2. Grillo-López AJ, Dallaire BK, McClure A, Weaver R, Varns C, Wei A, Allen R, Lee D, Shen D, Leonard J, Multani P, White CA: Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma. Curr Pharm Biotechnol; 2001 Dec;2(4):301-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma.
  • Monoclonal antibodies (MAbs) have been used as therapeutic agents for many years.
  • Herceptin (for patients with breast cancer) and Mylotarg (for patients with acute myeloid leukemia) were approved shortly thereafter.
  • Literally dozens of antibodies are currently under investigation for a variety of malignant and non-neoplastic indications.
  • Rituxan is effective in patients with low-grade or follicular, relapsed or refractory non-Hodgkin's lymphoma (NHL).
  • This marks the first time that any agent has shown results superior to CHOP, the curative gold standard for this type of NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11762412.001).
  • [ISSN] 1389-2010
  • [Journal-full-title] Current pharmaceutical biotechnology
  • [ISO-abbreviation] Curr Pharm Biotechnol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm
  • [Number-of-references] 79
  •  go-up   go-down


3. Mellstedt H: Monoclonal antibodies in human cancer. Drugs Today (Barc); 2003;39 Suppl C:1-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effect of antibodies can be enhanced by combination with chemotherapy and/or by agents which activate the immune system.
  • Rituximab (anti-CD20) was the first registered MAB for the therapy of follicular lymphoma.
  • Impressive results have been seen in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) in follicular and high-grade lymphomas.
  • In other non-Hodgkin's lymphoma subtypes, promising results are also seen in combination with chemotherapy.
  • Trastuzumab (anti-Her2) is a breakthrough in the treatment of breast cancer in combination with chemotherapeutic agents.
  • [MeSH-minor] Animals. Area Under Curve. Clinical Trials as Topic. Dose-Response Relationship, Drug. Drug Administration Schedule. Half-Life. Humans


Advertisement
4. Wang ES, O'Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA: Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma; 2003 Jun;44(6):1027-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.
  • In prior studies, PDX exhibited enhanced efficacy over methotrexate (MTX) in lung and breast carcinoma xenografts.
  • Because MTX is active in the treatment of aggressive non-Hodgkin's lymphoma (NHL), we compared the efficacy of PDX and MTX against five lymphoma cell lines: RL (transformed follicular lymphoma), HT, SKI-DLBCL-1 (diffuse large B cell), Raji (Burkitt's), and Hs445 (Hodgkin's disease).
  • Tumor bearing animals were treated with saline (control) or the maximum tolerated doses of MTX (40 mg/kg) or PDX (60 mg/kg) via an intraperitoneal route twice weekly for 2 weeks.
  • [MeSH-major] Aminopterin / analogs & derivatives. Aminopterin / toxicity. Cell Survival / drug effects. Lymphoma / drug therapy. Lymphoma / pathology. Methotrexate / toxicity
  • [MeSH-minor] Animals. Apoptosis / drug effects. Folic Acid Antagonists / therapeutic use. Folic Acid Antagonists / toxicity. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Transplantation, Heterologous. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AMINOPTERIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12854905.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-0172; United States / NCI NIH HHS / CA / CA-09207-24
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 10-propargyl-10-deazaaminopterin; 0 / Folic Acid Antagonists; JYB41CTM2Q / Aminopterin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Carver JR, Nasta S, Chong EA, Stonecypher M, Wheeler JE, Ahmadi T, Schuster SJ: Myocarditis during lenalidomide therapy. Ann Pharmacother; 2010 Nov;44(11):1840-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report the first case of pathologically confirmed myocarditis in a patient receiving treatment with lenalidomide for non-Hodgkin's lymphoma.
  • CASE SUMMARY: An 85-year-old woman with recurrent follicular lymphoma was treated with lenalidomide 10 mg daily and low-dose dexamethasone 8 mg once weekly in a clinical trial.
  • She had a past medical history of hypertension and breast cancer.
  • DISCUSSION: Lenalidomide is an immunomodulatory agent derived from thalidomide and is approved for the treatment of multiple myeloma and myelodysplastic syndromes.
  • CONCLUSIONS: Our findings suggest that lenalidomide may be a cause of drug-induced myocarditis.
  • When patients treated with lenalidomide present with signs and symptoms of heart failure in the absence of other obvious causes, lenalidomide hypersensitivity should be considered in the differential diagnosis and a myocardial biopsy should be considered when other common causes of heart failure have been excluded.
  • A reasonable management approach is drug discontinuation and early institution of corticosteroid therapy.
  • An objective causality assessment, using the Naranjo probability scale, revealed that the adverse drug event was probable.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Myocarditis / chemically induced. Thalidomide / analogs & derivatives
  • [MeSH-minor] Aged, 80 and over. Autopsy. Dexamethasone / therapeutic use. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Multiple Organ Failure / etiology. T-Lymphocytes / metabolism

  • Genetic Alliance. consumer health - Myocarditis.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876827.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down


6. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F: Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol; 2009 Mar 1;27(7):1122-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The antiepidermal growth factor receptor antibody cetuximab shows activity in irinotecan-refractory metastatic colorectal cancer (mCRC), mainly in wild-type KRAS tumors.
  • ADCC is influenced by FcgammaRIIa-H131R and FcgammaRIIIa-V158F polymorphisms that are clinically relevant in follicular lymphoma and metastatic breast cancer treated with rituximab and trastuzumab, respectively.
  • Patients with FcgammaRIIa-131H/H and/or FcgammaIIIa-158V/V genotypes had longer PFS than 131R and 158F carriers (5.5 v 3.0 months; P = .005).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / genetics. Drug Resistance, Neoplasm / genetics. Mutation. Polymorphism, Genetic. Proto-Oncogene Proteins / genetics. Receptors, IgG / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164213.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Fc gamma receptor IIA; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, IgG; 7673326042 / irinotecan; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Yang S, Evens AM, Prachand S, Singh AT, Bhalla S, David K, Gordon LI: Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata. Clin Cancer Res; 2010 Oct 1;16(19):4755-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata.
  • PURPOSE: Andrographolide is a diterpenoid lactone isolated from Andrographis paniculata (King of Bitters), an herbal medicine used in Asia.
  • EXPERIMENTAL DESIGN: We studied the Burkitt p53-mutated Ramos cell line, the mantle cell lymphoma (MCL) line Granta, the follicular lymphoma (FL) cell line HF-1, and the diffuse large B-cell lymphoma (DLBCL) cell line SUDHL4, as well as primary cells from patients with FL, DLBCL, and MCL.
  • To determine mechanism of cell death, we measured apoptosis by Annexin V/propidium iodide in the presence and absence of the antioxidant N-acetyl-l-cysteine (NAC), the glutathione (GSH)-depleting agent buthionine sulfoxamine (BSO), or caspase inhibitors.
  • CONCLUSIONS: Andrographolide caused ROS-dependent apoptosis in lymphoma cell lines and in primary tumor samples, which was enhanced by depletion of GSH and inhibited by NAC or the pan-caspase inhibitor Z-VAD-FMK.
  • Further studies of diterpenoid lactones in lymphoma are warranted.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Phytomedicine. 2000 Oct;7(5):351-64 [11081986.001]
  • [Cites] J Exp Ther Oncol. 2003 May-Jun;3(3):147-58 [14641821.001]
  • [Cites] J Clin Pharm Ther. 2004 Feb;29(1):37-45 [14748896.001]
  • [Cites] J Ethnopharmacol. 2004 Jun;92(2-3):291-5 [15138014.001]
  • [Cites] BMC Cancer. 2004 Jun 18;4:26 [15207007.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Sep 20;14(18):4711-7 [15324893.001]
  • [Cites] J Immunol. 2004 Sep 15;173(6):4207-17 [15356172.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Biochem J. 1999 Feb 15;338 ( Pt 1):107-13 [9931305.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Jan;312(1):366-72 [15331658.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1265-73 [15388578.001]
  • [Cites] Mol Cell. 2005 Feb 18;17(4):525-35 [15721256.001]
  • [Cites] Br J Pharmacol. 2005 Mar;144(5):680-6 [15678086.001]
  • [Cites] In Vivo. 2005 May-Jun;19(3):551-7 [15875775.001]
  • [Cites] Planta Med. 2005 Dec;71(12):1106-11 [16395645.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2501-6 [16291594.001]
  • [Cites] Biochem Pharmacol. 2006 Jul 14;72(2):132-44 [16740251.001]
  • [Cites] Pak J Pharm Sci. 2007 Jan;20(1):9-15 [17337421.001]
  • [Cites] Methods. 2008 Mar;44(3):229-34 [18314053.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Apr;325(1):226-35 [18174384.001]
  • [Cites] J Asian Nat Prod Res. 2008 May-Jun;10(5-6):467-73 [18464090.001]
  • [Cites] J Nat Prod. 2008 May;71(5):852-5 [18357994.001]
  • [Cites] J Cell Sci. 2008 Jul 1;121(Pt 13):2186-96 [18544634.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):2170-80 [18645026.001]
  • [Cites] Zhong Xi Yi Jie He Xue Bao. 2008 Dec;6(12):1238-45 [19063836.001]
  • [Cites] J Pharm Pharmacol. 2009 Jan;61(1):69-78 [19126299.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):502-6 [19158000.001]
  • [Cites] Breast Cancer Res. 2008;10(6):R104 [19061505.001]
  • [Cites] Cancer Lett. 2009 Apr 18;276(2):180-8 [19097688.001]
  • [Cites] Drug Metab Lett. 2008 Dec;2(4):261-8 [19356103.001]
  • [Cites] Oncogene. 2009 Jul 23;28(29):2690-6 [19503098.001]
  • [Cites] Int J Toxicol. 2009 Jul-Aug;28(4):308-17 [19636073.001]
  • [Cites] Redox Rep. 2009;14(4):176-84 [19695125.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1232-9 [20610044.001]
  • [Cites] Phytother Res. 2000 Aug;14(5):333-8 [10925397.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • (PMID = 20798229.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA109613; United States / NCI NIH HHS / CA / K23 CA109613-A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diterpenes; 0 / Reactive Oxygen Species; 410105JHGR / andrographolide
  • [Other-IDs] NLM/ NIHMS231241; NLM/ PMC2948634
  •  go-up   go-down


8. Mitrofan LM, Castells FB, Pelkonen J, Mönkkönen J: Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in human follicular lymphoma cells. J Biol Chem; 2010 Jan 15;285(3):1967-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in human follicular lymphoma cells.
  • Zoledronic acid (ZOL) represents a potential chemotherapeutic agent for the treatment of cancer.
  • Recently we demonstrated that accumulation of isopentenyl pyrophosphate and the consequent formation of a new type of ATP analog (ApppI) after mevalonate pathway inhibition by nitrogen-containing BPs strongly correlates with ZOL-induced cell death in cancer cells in vitro.
  • In this study we show that ZOL-induced apoptosis in HF28RA human follicular lymphoma cells occurs exclusively via the mitochondrial pathway, involves lysosomes, and is dependent on mevalonate pathway inhibition.
  • Moreover, we show a potential regulation by Bcl-XL and caspase-9 on cell cycle regulators of S-phase.
  • [MeSH-major] Apoptosis / drug effects. Diphosphonates / pharmacology. Imidazoles / pharmacology. Lymphoma, Follicular / pathology. Lysosomes / metabolism. Mitochondria / metabolism
  • [MeSH-minor] Adenosine Triphosphate / analogs & derivatives. Adenosine Triphosphate / metabolism. Animals. Caspase Inhibitors. Cathepsins / antagonists & inhibitors. Cattle. Cell Line, Tumor. Cell Membrane Permeability / drug effects. Hemiterpenes / metabolism. Humans. Mevalonic Acid / metabolism. Mice. Organophosphorus Compounds / metabolism. Prenylation / drug effects. Protease Inhibitors / pharmacology. Signal Transduction / drug effects. bcl-X Protein / metabolism

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. MEVALONIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Jun;290(6):G1339-46 [16484678.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Oct 14;264(1):108-11 [10527849.001]
  • [Cites] Surgery. 2006 Aug;140(2):227-35 [16904974.001]
  • [Cites] Breast. 2004 Dec;13 Suppl 1:S19-28 [15585379.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):2993-5 [15833821.001]
  • [Cites] Leukemia. 2005 May;19(5):784-91 [15759029.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):336-43 [15922292.001]
  • [Cites] Leukemia. 2005 Nov;19(11):1896-904 [16167056.001]
  • [Cites] Br J Pharmacol. 2006 Feb;147(4):437-45 [16402039.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):589-98 [11483992.001]
  • [Cites] Nat Cell Biol. 2001 Nov;3(11):E255-63 [11715037.001]
  • [Cites] J Immunol Methods. 2002 Jul 1;265(1-2):39-47 [12072177.001]
  • [Cites] Lancet. 2002 Jun 8;359(9322):2018-26 [12076571.001]
  • [Cites] J Cell Physiol. 2002 Aug;192(2):131-7 [12115719.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34287-94 [12097332.001]
  • [Cites] Biol Chem. 2002 Jul-Aug;383(7-8):1035-44 [12437086.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):840-7 [12548584.001]
  • [Cites] J Exp Med. 2003 May 19;197(10):1323-34 [12756268.001]
  • [Cites] Mol Aspects Med. 2006 Oct-Dec;27(5-6):471-82 [16973208.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):7880-91 [16966373.001]
  • [Cites] Mol Pharmacol. 2007 Jan;71(1):333-43 [17050806.001]
  • [Cites] J Thromb Haemost. 2007 Jan;5(1):166-73 [17059425.001]
  • [Cites] Apoptosis. 2007 Jul;12(7):1257-67 [17347868.001]
  • [Cites] Oncogene. 2007 Aug 30;26(40):5851-65 [17369848.001]
  • [Cites] Apoptosis. 2008 Jun;13(6):782-9 [18437576.001]
  • [Cites] J Biol Chem. 2008 Jul 4;283(27):19140-50 [18469004.001]
  • [Cites] Cancer Treat Rev. 2008 Aug;34(5):453-75 [18423992.001]
  • [Cites] Osteoporos Int. 2008 Jun;19(6):733-59 [18214569.001]
  • [Cites] Oncogene. 2008 Oct 27;27(50):6434-51 [18955971.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):667-76 [19036117.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):679-91 [19213681.001]
  • [Cites] Leuk Res. 2009 Jun;33(6):829-36 [18977530.001]
  • [Cites] Apoptosis. 2009 May;14(5):687-98 [19308735.001]
  • [Cites] Bone. 2009 Dec;45(6):1153-60 [19699819.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1971-8 [12799645.001]
  • [Cites] Drugs. 1999 Nov;58(5):823-30 [10595863.001]
  • [Cites] Nat Med. 2000 May;6(5):513-9 [10802706.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] J Bone Miner Res. 2000 Nov;15(11):2211-21 [11092402.001]
  • [Cites] Oncogene. 2000 Dec 14;19(54):6342-50 [11175349.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1126-34 [11308265.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1063-75 [11314043.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3149-57 [11073962.001]
  • [Cites] Adv Enzyme Regul. 2001;41:237-50 [11384748.001]
  • [Cites] Trends Biochem Sci. 2001 Jun;26(6):390-7 [11406413.001]
  • [Cites] Eur J Biochem. 2003 Sep;270(18):3778-86 [12950261.001]
  • [Cites] Bone. 2003 Aug;33(2):216-28 [14499355.001]
  • [Cites] EMBO J. 2003 Oct 15;22(20):5459-70 [14532118.001]
  • [Cites] J Biol Chem. 2004 Jan 30;279(5):3578-87 [14581476.001]
  • [Cites] BJU Int. 2004 Jul;94(1):164-70 [15217454.001]
  • [Cites] Photochem Photobiol. 1990 Jan;51(1):67-76 [2304980.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Calcif Tissue Int. 1991 Dec;49(6):407-15 [1840176.001]
  • [Cites] Annu Rev Genet. 1992;26:209-37 [1482112.001]
  • [Cites] Cell. 1996 Jul 12;86(1):147-57 [8689682.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):9677-82 [9092497.001]
  • [Cites] Nat Med. 1997 Jun;3(6):614-20 [9176486.001]
  • [Cites] EMBO J. 1998 Jan 2;17(1):37-49 [9427739.001]
  • [Cites] Leukemia. 1998 Feb;12(2):220-9 [9519785.001]
  • [Cites] J Bone Miner Res. 1998 Apr;13(4):581-9 [9556058.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):133-8 [9874784.001]
  • [Cites] Genes Dev. 1999 Aug 1;13(15):1899-911 [10444588.001]
  • [Cites] J Bone Miner Res. 2006 May;21(5):684-94 [16734383.001]
  • (PMID = 19875454.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caspase Inhibitors; 0 / Diphosphonates; 0 / Hemiterpenes; 0 / Imidazoles; 0 / Organophosphorus Compounds; 0 / Protease Inhibitors; 0 / bcl-X Protein; 358-71-4 / isopentenyl pyrophosphate; 6XC1PAD3KF / zoledronic acid; 8L70Q75FXE / Adenosine Triphosphate; EC 3.4.- / Cathepsins; S5UOB36OCZ / Mevalonic Acid
  • [Other-IDs] NLM/ PMC2804355
  •  go-up   go-down


9. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB: In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des; 2000 Apr;15(2):151-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines.
  • The in vitro cytotoxic and lytic activity of short mammalian-derived extended-helical cationic peptides and insect-derived alpha-helical peptides was measured in this study with the objective of establishing the anticancer potential of these agents.
  • Two specific aims were addressed: (i) to assess the activity of peptides against non-malignant cells (sheep erythrocytes and human umbilical vein endothelial cells) versus tumor cells; and (ii) to characterize the cytotoxic activity using multidrug-resistant tumor cell lines in the presence and absence of the anthracycline doxorubicin.
  • Cell lysis assays demonstrated that the lytic activity of the peptides tested was 2->50 times more cytotoxic to tumor cells than to non-malignant cells.
  • [MeSH-major] Antineoplastic Agents / toxicity. Cell Survival / drug effects. Doxorubicin / toxicity. Drug Resistance, Multiple. P-Glycoprotein / physiology. Peptides / toxicity
  • [MeSH-minor] Amino Acid Sequence. Animals. Breast Neoplasms. Carcinoma, Non-Small-Cell Lung. Drug Synergism. Female. Hemolysis / drug effects. Humans. K562 Cells. Leukemia P388. Leukemia, Erythroblastic, Acute. Lung Neoplasms. Lymphoma, Follicular. Mice. Molecular Sequence Data. Oligopeptides / chemistry. Oligopeptides / toxicity. Protein Structure, Secondary. Sheep. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10901303.001).
  • [ISSN] 0266-9536
  • [Journal-full-title] Anti-cancer drug design
  • [ISO-abbreviation] Anticancer Drug Des.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oligopeptides; 0 / P-Glycoprotein; 0 / Peptides; 80168379AG / Doxorubicin
  •  go-up   go-down


10. Ishizawa S, Slovak ML, Popplewell L, Bedell V, Wrede JE, Carter NH, Snyder DS, Arber DA: High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities. Leukemia; 2003 Jun;17(6):1091-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight ALL cases with a prior diagnosis of malignancy were identified, including six (4.0%) with prior therapy considered to be therapy-related ALL (t-ALL).
  • The t-ALL cases followed treatment for breast carcinoma (two cases), lung carcinoma (two cases), lymphocyte predominance Hodgkin's disease and follicular lymphoma with a latency period of 13 months to 8 years.
  • All t-ALL cases had a pro-B (CD10-negative) immunophenotype with significantly higher expression of CD15 and CD65, compared to the de novo CD10-positive ALL cases.
  • The immunogenetic features of t-ALL appear distinct and may aid in identifying more cases of this disease type in the future.
  • [MeSH-major] Burkitt Lymphoma / etiology. Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Leukemia, Myeloid / etiology. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Antigens, CD / immunology. Antineoplastic Agents / therapeutic use. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Neoplasms / drug therapy. Neoplasms / radiotherapy. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12764373.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 30206; United States / NCI NIH HHS / CA / CA 33572
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antineoplastic Agents
  •  go-up   go-down


11. Hemminki K, Eng C, Chen B: Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab; 2005 Oct;90(10):5747-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Systematized Nomenclature of Medicine histology was available from 1993 onward, with 1449 papillary, 288 follicular, 148 anaplastic, and 68 Hurthle cell tumors.
  • Associations found in single comparisons with papillary thyroid cancer and other sites included right-sided colon, breast, ovarian, and kidney cancers.
  • Hurthle cell tumors were associated with Hodgkin's and non-Hodgkin's lymphoma, but the numbers of cases were small.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030170.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Cheson BD, Rummel MJ: Bendamustine: rebirth of an old drug. J Clin Oncol; 2009 Mar 20;27(9):1492-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bendamustine: rebirth of an old drug.
  • Bendamustine is a unique cytotoxic agent with structural similarities to alkylating agents and antimetabolites, but which is non-cross-resistant with alkylating agents and other drugs in vitro and in the clinic.
  • Early clinical studies conducted in the German Democratic Republic more than 30 years ago suggested promising activity in indolent non-Hodgkin's lymphoma (NHL).
  • Two North American trials reported responses in more than 70% of patients with chemotherapy- and rituximab-refractory disease, suggesting that bendamustine may be the most effective drug available for this patient population.
  • Response rates of 90% to 92%, with complete remission in 55% to 60%, have been reported in patients with follicular and mantle-cell lymphoma with the combination of bendamustine and rituximab.
  • Activity has also been noted in patients with breast cancer and small-cell lung cancer [corrected].
  • Questions related to the optimization of bendamustine therapy, including dose and schedule, role relative to other available agents, and management of toxicities, are being investigated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Nitrogen Mustard Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Bendamustine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2009 Jun 10;27(17):2892
  • (PMID = 19224851.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride
  • [Number-of-references] 66
  •  go-up   go-down


13. Kim JA: Targeted therapies for the treatment of cancer. Am J Surg; 2003 Sep;186(3):264-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In contrast to conventional cytotoxic chemotherapy and radiation therapy, a new method of targeted cancer therapeutics is being directed towards molecular pathways that underlie the malignant phenotype.
  • Rituxan is a humanized monoclonal antibody that binds to the CD20 antigen present on B cell lymphomas and is currently approved for the treatment of patients with relapsed or refractory low-grade CD20 positive follicular lymphoma.
  • The humanized anti-HER-2/neu herceptin is approved for use in patients with metastatic breast cancer that demonstrates overexpression of HER-2/neu.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Benzamides. Breast Neoplasms / drug therapy. Female. Humans. Imatinib Mesylate. Lymphoma, B-Cell / drug therapy. Male. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. Rituximab. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12946830.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 4F4X42SYQ6 / Rituximab; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; P188ANX8CK / Trastuzumab
  • [Number-of-references] 32
  •  go-up   go-down


14. Glimelius B, Bergh J, Brandt L, Brorsson B, Gunnars B, Hafström L, Haglund U, Högberg T, Janunger KG, Jönsson PE, Karlsson G, Kimby E, Lamnevik G, Nilsson S, Permert J, Ragnhammar P, Sörenson S, Nygren P: The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions. Acta Oncol; 2001;40(2-3):135-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixteen experts representing different disciplines (oncology, surgery, internal medicine, health economy and quality of life research) participated in the literature review.
  • Secondly, the two tumour types comprising the greatest number of patients treated with chemotherapy in Sweden, breast cancer and haematological malignancies, were included.
  • Among the haematological malignancies, the most prevalent ones, acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL), Hodgkin's disease (HD), aggressive non-Hodgkin's lymphoma (NHL) of the large B-cell type and indolent NHL of follicular type were evaluated.
  • Thirdly, ovarian cancer was included since chemotherapy has been extensively used and since, at the time of the planning of this overview, a group of very expensive drugs, the taxanes, had preliminarily shown promising results.
  • The survey of practice of chemotherapy use involved all departments of surgery, urology, gynaecology, internal medicine including haematologic units, pulmonary medicine and general and gynaecologic oncology at 16 hospitals in two health care regions in Sweden, covering 39% of the Swedish population.
  • The working group's general conclusions are summarised in the following points: The literature on the effects of chemotherapy is extensive.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Technology Assessment, Biomedical
  • [MeSH-minor] Cost-Benefit Analysis. Decision Making. Drug Costs. Evidence-Based Medicine. Humans. Sweden

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11441927.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 17
  •  go-up   go-down


15. Tímár J, Kásler M, Kátai J, Soós M, Mathiasz D, Romány A, Patthy L, Kovács G, Józsa A, Szilák L, Forrai T: [Developments in cancer management by innovative genomics. 2006 report of the National Cancer Consortium]. Magy Onkol; 2006;50(4):349-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Research on developing molecular diagnostics for hereditary cancers resulted in establishing diagnostic services for familiar polyposis and non-polyposis patients (mutation determination of APC, MYH, STK11, SMAD4, MLH1, MSH2).
  • Molecular diagnostic tool was established to monitor the progression of follicular lymphoma using Bcl-2/IgH fusion sequences.
  • Molecular diagnostic tools were developed to monitor circulating endothelial precursor cells (CEP) as well and the technique was tested in lung cancer patients.
  • In malignant melanoma we have tested several potential novel markers among which ryanodine receptor seems to be a promising one, while the functional P2X7 receptor may serve as a therapeutic target.
  • We have determined the tyrosine kinase "kinome" profile of HER-2-amplified breast cancers.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Biomarkers, Tumor / genetics. Genomics. Mutation. Neoplasms / diagnosis. Neoplasms / genetics
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Disease Progression. Female. Glycine Hydroxymethyltransferase / genetics. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / genetics. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Male. Melanoma / diagnosis. Melanoma / genetics. Neovascularization, Pathologic / diagnosis. Neovascularization, Pathologic / drug therapy. Pharmacogenetics. Polymorphism, Genetic. Prognosis. Receptors, Purinergic P2 / drug effects. Receptors, Purinergic P2X7. Ryanodine Receptor Calcium Release Channel / drug effects. Testicular Neoplasms / diagnosis. Testicular Neoplasms / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17216011.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / P2RX7 protein, human; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X7; 0 / Ryanodine Receptor Calcium Release Channel; EC 2.1.2.1 / Glycine Hydroxymethyltransferase
  • [Number-of-references] 15
  •  go-up   go-down


16. Hoyer KK, Pang M, Gui D, Shintaku IP, Kuwabara I, Liu FT, Said JW, Baum LG, Teitell MA: An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol; 2004 Mar;164(3):893-902
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased resistance to apoptosis promotes lymphomagenesis with aberrant expression of cell survival proteins such as BCL-2 and c-MYC occurring in distinct lymphoma subtypes.
  • Galectin-3 is an anti-apoptotic protein that protects T cells, macrophages, and breast carcinoma cells from death triggered by a variety of agents.
  • We have found high levels of galectin-3 protein expression in a subset of B-cell neoplasms including diffuse large B-cell lymphoma (DLBCL), primary effusion lymphoma (PEL), and multiple myeloma (MM), in both cell lines and patient samples.
  • However, we failed to detect galectin-3 in Burkitt lymphoma (BL), follicular lymphoma (FL), marginal zone lymphoma (MZL), MALT lymphoma or B-small lymphocytic lymphoma (B-SLL) cell lines or patient samples.

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1997 Jun;182(2):125-7 [9274520.001]
  • [Cites] J Pathol. 1997 Jun;182(2):145-50 [9274523.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5272-6 [9393748.001]
  • [Cites] Biochemistry. 1998 Mar 24;37(12):4086-92 [9521730.001]
  • [Cites] J Mol Med (Berl). 1998 May;76(6):402-12 [9625297.001]
  • [Cites] Semin Oncol. 1998 Aug;25(4):483-91 [9728598.001]
  • [Cites] Immunology. 1998 Jul;94(3):290-6 [9767409.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Int J Cancer. 2000 Feb 15;85(4):545-54 [10699929.001]
  • [Cites] J Neurosci Res. 2000 Apr 1;60(1):45-57 [10723067.001]
  • [Cites] J Cell Sci. 2000 Jul;113 ( Pt 13):2385-97 [10852818.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):2156-64 [10925302.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12250-5 [11035774.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3707-21 [11054444.001]
  • [Cites] Trends Biochem Sci. 2001 Jan;26(1):61-6 [11165519.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):787-92 [11251175.001]
  • [Cites] J Histochem Cytochem. 2001 Apr;49(4):539-49 [11259457.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):661-8 [11297262.001]
  • [Cites] Lab Invest. 2001 Apr;81(4):555-64 [11304575.001]
  • [Cites] J Leukoc Biol. 2001 Apr;69(4):555-64 [11310841.001]
  • [Cites] Biochimie. 2001 Jul;83(7):667-76 [11522396.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):34089-97 [11435439.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):1055-60 [11549597.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Blood. 2002 Jan 15;99(2):409-26 [11781220.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3487-97 [11706006.001]
  • [Cites] Annu Rev Med. 2002;53:303-18 [11818476.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6852-7 [11724777.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):1069-75 [11891203.001]
  • [Cites] C R Acad Sci III. 1996 Oct;319(10):871-7 [8977767.001]
  • [Cites] J Biol Chem. 1997 Feb 28;272(9):6078-86 [9038233.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2508-15 [9192833.001]
  • [Cites] Exp Cell Res. 1998 Dec 15;245(2):294-302 [9851870.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3225-36 [9916985.001]
  • [Cites] Glycobiology. 1999 Apr;9(4):383-7 [10089212.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7 Suppl):1693s-1700s [10197582.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):519-26 [10225438.001]
  • [Cites] Blood. 1999 Jul 15;94(2):701-12 [10397737.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9809-14 [10449776.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):15819-27 [11839755.001]
  • [Cites] Trends Immunol. 2002 Jun;23(6):313-20 [12072371.001]
  • [Cites] Clin Immunol. 2002 Jun;103(3 Pt 1):217-30 [12173296.001]
  • [Cites] Semin Cancer Biol. 2002 Oct;12(5):381-7 [12191637.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 19;1572(2-3):263-73 [12223274.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 19;1572(2-3):285-93 [12223276.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2374-83 [12796408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] Int J Cancer. 1980 Feb 15;25(2):261-5 [6967054.001]
  • [Cites] Mutat Res. 1982 Nov;105(5):337-42 [7144791.001]
  • [Cites] Lab Invest. 1988 May;58(5):524-31 [3285097.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):871-7 [2228316.001]
  • [Cites] Cell. 1991 Jul 26;66(2):233-43 [1713127.001]
  • [Cites] Am J Pathol. 1992 May;140(5):1089-95 [1374590.001]
  • [Cites] J Biol Chem. 1992 Jul 15;267(20):14167-74 [1629216.001]
  • [Cites] Gene. 1993 May 30;127(2):267-8 [8500769.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1067-78 [8111047.001]
  • [Cites] Biol Cell. 1994;81(1):73-6 [7987244.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1449-56 [7533326.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2818-26 [7773932.001]
  • [Cites] APMIS. 1995 Sep;103(9):655-62 [7488387.001]
  • [Cites] Nature. 1995 Dec 14;378(6558):736-9 [7501023.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):25-30 [8546213.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1661-70 [8623933.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6737-42 [8692888.001]
  • [Cites] Blood. 1996 Jul 15;88(2):386-401 [8695785.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] FEBS Lett. 2000 Jan 21;466(1):6-10 [10648802.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):776-87 [9264362.001]
  • (PMID = 14982843.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA90571; United States / NIAID NIH HHS / AI / R01 AI020958; United States / NCI NIH HHS / CA / R01 CA107300; United States / NCI NIH HHS / CA / R01 CA090571; United States / NIGMS NIH HHS / GM / GM63281; United States / NCI NIH HHS / CA / CA107300; United States / NIAID NIH HHS / AI / R01 AI039620; United States / NIAID NIH HHS / AI / AI20958; United States / NIGMS NIH HHS / GM / R01 GM063281; United States / NCI NIH HHS / CA / T32CA090056; United States / NIAID NIH HHS / AI / AI39620
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Galectin 3
  • [Other-IDs] NLM/ PMC1614710
  •  go-up   go-down






Advertisement